Inhibition by Phenol and Phenolic Acids of Platelet Release Reaction

Summary

It has been postulated that the high phenol and phenolic acids plasmatic levels found in patients with chronic renal failure are contributory factors in the abnormal platelet function described in these patients. This hypothesis was corroborated by “in vitro” studies showing the deleterious effect of these compounds on certain platelet function after pre-incubation of PRP with phenol and phenolic compounds. The present studies were conducted to determine the influence of phenolic compounds on platelet release reaction. It was found that phenol inhibited from 62.5 to 100% the effect of the aggregating agents thrombin, adrenaline and ADP on platelet 5-HT-¹⁴C release. The phenolic acids p-, m-, and o-HPAA inhibited from 36.35 to 94.8% adrenaline and ADP-induced platelet 5-HT-¹⁴C release. Adrenaline-induced platelet ADP release was inhibited from 27.45 to 38.10% by the phenolic compounds. These findings confirm the hypothesis that phenolic compounds interfere with platelet function through the inhibition of the release reaction.

• References

• 1 Brecher G, and Cronkite Z. P. 1950; Morphology and enumeration of blood platelets. Journal of Applied Physiology 3: 365.
• 2 Cayton S. C, Born R. G, and Cross M. J. 1963; Inhibition of the aggregation of blood platelets by nucleotides. Nature 200: 138.
• 3 Glynn M. F, Movat H. Z, Murphy E. A, and Mustard J. F. 1965; Study of platelet adhesiveness and aggregation with latex particles. Journal of Laboratory and Clinical Medicine 65: 179.
• 4 Jutzler G, Kramer H. J, Keller H. H, Kramer H, and Doenecke F. 1968; Zum Verhalten der Phenole und des Kreatinins bei Niereninsuffizienz, insbesondere bei chronischen Dialyse-Patienten. Archiv für Klinische Medizin 214: 214.
• 5 Marcus A. J, Zucker-Franklin D, Safier L. B, and Ullman H. L. 1966; Studies on Human Platelet Granules and Membranes. Journal of Clinical Investigation 45: 14.
• 6 Mills D. C. B, and Roberts G. C. 1967; Membrane Active Drugs and the Aggregation of Human Blood Platelets. Nature 212: 35.
• 7 Mills D. C. B, Robb I. A, and Roberts G. C. 1968; The release of nucleotides, 5-hydroxytryptamine and enzymes from human blood platelets during aggregation. Journal of Physiology 195: 715.
• 8 O’Brien J. R, Finch W, and Clark E. 1970; Platelet-bound and Soluble Platelet Factor 4: Effects of Aggregating Agents, of Aggregation, and of Aspirin. Proceedings of the Society of Experimental Biology and Medicine 134: 1120.
• 9 Rabiner S. F, and Hrodek O. 1968; Platelet Factor 3 in Normal Subjects and Patients with Renal Failure. Journal of Clinical Investigation 47: 901.
• 10 Rabiner S. F, and Molinas F. 1970; The Role of Phenol and Phenolic Acids on the Thrombo- cytopathy and Defective Platelet Aggregation of Patients with Renal Failure. American Journal of Medicine 49: 346.
• 11 Robinson C. W, Mason R. G, and Wagner R. H. 1963; Effect of sulphydryl inhibitors on platelet agglutinability. Proceedings of the Society of Experimental Biology and Medicine 113: 857.
• 12 Salzman E. W, and Chambers D. A. 1964; Inhibition of ADP-induced platelet aggregation by substituted aminoacids. Nature 204: 698.
• 13 Steffen J, Ryszard C, and Kazimiers B. 1961; The influence of hemodialysis on the level of free phenols in the blood of patients with renal failure. Poznañskie Towarzystwo Przyjaciol Nauk Wydzial Lekarski 21: 147.
• 14 Stewart J. H, and Castaldi P. A. 1967; Uremic bleeding: a reversible platelet defect corrected by dialysis. Quarterly Journal of Medicine 36: 409.
• 15 Wardle E. N. 1970; A Study of the Effects of Possible Toxic Metabolites of Uremic on Red Cell Metabolism. Acta haematologica 43: 129.
• 16 Zucker M. B, and Peterson J. 1967; Serotonin, platelet factor 3 activity, and platelet-aggregating agents released by adenosine diphosphate. Blood 30: 556.
• 17 Zweifler A. J, and Sanbar S. S. 1969; Inhibition of platelet adhesiveness and aggregation by benzyl alcohol and phenol. Thrombosis et Diathesis Haemorrhagica 21: 362.